Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
Japan’s key reimbursement policy panel on March 12 gave the blessing to a batch of new medicines for listing later this month, including Eli Lilly’s obesity drug Zepbound (tirzepatide) and Biogen’s amyotrophic lateral sclerosis (ALS) treatment Qalsody (tofersen). A total…
To read the full story
Related Article
- UCB Japan Launches IV Form of Epilepsy Med Briviact
April 18, 2025
- Pfizer Rolls Out Hemophilia Therapy Hympavzi in Japan
March 25, 2025
- Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11
March 21, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Biogen Japan to Launch ALS Drug Qalsody upon Listing on March 19
March 14, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
- Imdelltra, Balversa, 2 More New Drugs Skip March Listing
March 13, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
REGULATORY
- Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
- Japan Eyes Multi-Year Investment Support for Wholesalers in FY2027 Budget
November 6, 2026
- Japan Poised to Broker Generic Firms’ Product Consolidation Talks
November 6, 2026
- Japan Issues Guidance on AI Model Use in Drug Manufacturing, Quality Control
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…